 BOSTON, Jan. 05, 2021 GLOBE NEWSWIRE -- Rhythm Pharmaceuticals, Inc. Nasdaq:RYTM, a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher PRV for 100M. 